Stability and reliability of objective measures of speech in Parkinson’s Disease over 12 months
Objective: To describe the stability and reliability of acoustic measures of speech in Parkinson’s Disease (PD) at 3 and 12 months. Background: Speech biomarkers hold…Correlation between structural neuroimaging and clinical outcomes in a small sample of patients with early Huntington’s disease
Objective: Scores on the symbol digit modalities test (SDMT), Stroop word-reading, Total Motor Score (TMS) and composite UHDRS (cUHDRS) are correlated with disease progression and…Seeking regulatory feedback on novel clinical outcome assessments: a case example from the Huntington’s Disease – Regulatory Science Consortium (HD-RSC)
Objective: To align with regulators on the utility and development strategy of novel clinical outcome assessments for use in Huntington’s disease (HD) clinical trials. Background:…A safety, tolerability and biomarker update from an ongoing open-label extension study of RG6042 in adults with early manifest Huntington’s disease
Objective: To present the safety, tolerability and biomarker effects of RG6042 (previously, IONIS-HTTRX) during an open-label extension (OLE) study in adults with early manifest Huntington’s…Onset of action for rimabotulinumtoxinB in the treatment of adult sialorrhea
Objective: To assess the onset of action for rimabotulinumtoxinBinjections in the salivary glands for the treatment of sialorrhea. Background: Sialorrhea (drooling) causes significant morbidity including impaired oral…Incidence of treatment-emergent adverse events in Parkinson’s disease patients according to baseline MAO-B inhibitors use: post-hoc analysis from double-blind combined BIPARK-I and II data
Objective: To evaluate the incidence of treatment-emergent adverse events (TEAEs) in levodopa-treated Parkinson’s Disease (PD) patients with motor fluctuations and taking opicapone (OPC). Background: OPC…Intestinal Levodopa/Carbidopa Infusion as a Therapeutic Option for Freezing of Gait After Deep Brain Stimulation in Parkinson’s Disease
Objective: The study of the benefit of intestinal levodopa/carbidopa infusion(LCIG) in resistant ON-freezing of gait(FOG-ON) that appears after Subthalamic Nucleus Deep Brain Stimulation(NST-DBS) in Parkinson’s…Efficacy of carbidopa/levodopa enteral suspension (CLES) in advanced Parkinson’s disease patients previously treated with deep brain stimulation (DBS) – A subgroup analysis from PROviDE study
Objective: To evaluate the effectiveness of carbidopa/levodopa enteral suspension (CLES) on patients with advanced Parkinson’s disease who had previously undergone deep brain stimulation (DBS). Background:…Use of Inappropriate Antipsychotics Among US Long-Term Care Residents with Parkinson’s Disease Psychosis
Objective: To characterize the use of inappropriate antipsychotic therapies among residents with Parkinson’s disease psychosis (PDP) in long-term care (LTC) settings in the US. Background:…OPICAPONE: REAL WORLD EVIDENCE IN TOLEDO´S MOVEMENT DISORDERS UNIT
Objective: We present a prospective observational-real life study about the use in Movement Disorders Unit´s patients, since its commercialization in Spain (June 2017). Background: The…
- « Previous Page
- 1
- …
- 40
- 41
- 42
- 43
- 44
- …
- 217
- Next Page »